Adding Darolutamide to Standard Therapy Halves Metastasis Risk in High-Risk Prostate Cancer

Men diagnosed with very high-risk localized prostate cancer face a daunting prognosis, as their tumors frequently escape the prostate despite aggressive initial treatment. New phase 3 clinical trial data presented at the 2026 European Society for Medical Oncology (ESMO) congress demonstrates that adding the drug darolutamide to standard therapy cuts the risk of the disease spreading by 58 percent.[4][6]

The findings from the DASL-HiCaP trial offer a highly effective new protocol for patients whose cancer is confined to the pelvic region but exhibits aggressive microscopic features. Prostate cancer accounts for roughly 29 percent of all new cancer diagnoses in men, and those in the highest risk tier require immediate, intensive intervention.[2][5]

For decades, the standard of care has relied on a combination of pelvic radiation and foundational androgen deprivation therapy (ADT). While that conventional dual approach cures many patients, historically up to 30 percent of men in this specific high-risk tier experience a biochemical recurrence within five years.[1][2]

These recurrences happen because patients often harbor microscopic cancer cells that have already entered the bloodstream before radiation begins. These undetectable rogue cells eventually seed new tumors in the bones or lymph nodes, transforming a localized problem into a systemic, incurable disease.[1][5]

Blocking the androgen receptor

To close this treatment gap, researchers hypothesized that intensifying the initial hormone blockade could starve these microscopic cells before they establish distant footholds. The international trial enrolled 1,125 men, randomizing them to receive either standard ADT and radiation alone, or the standard regimen plus darolutamide for 96 weeks.[2][5]

Darolutamide, marketed by Bayer under the brand name Nubeqa, belongs to a class of medications known as androgen receptor inhibitors. Prostate cancer cells rely heavily on testosterone and related androgens to fuel their rapid cellular division and structural growth.[3][4]

Traditional ADT works by shutting down the body’s primary testosterone production in the testicles, drastically lowering circulating hormone levels. However, the adrenal glands and even the prostate tumor cells themselves can continue to produce small amounts of androgens, which is often enough to keep the cancer alive.[1][5]

Darolutamide addresses this vulnerability by binding directly to the androgen receptors on the cancer cells, physically blocking any remaining hormones from attaching and delivering growth signals. By combining this direct receptor blockade with traditional ADT, oncologists can achieve a much deeper and more comprehensive starvation of the tumor.[3][6]

The results of this intensified approach were striking. At the primary analysis point, patients receiving the darolutamide combination experienced a 58 percent reduction in the risk of metastasis or death compared to those receiving the standard of care.[4][6]

"The significant improvement in metastasis-free survival observed in this trial provides compelling evidence for intensifying treatment in this high-risk setting," noted the lead study investigators in their presentation, emphasizing that the data supports a fundamental shift in clinical practice.[1][6]

Preserving quality of life

While intensifying cancer treatment often comes at the cost of severe side effects, the DASL-HiCaP data indicates that darolutamide maintains a highly favorable safety profile. This is a critical consideration for men who are already enduring the fatigue, hot flashes, and metabolic changes associated with traditional hormone suppression.[2][3]

Unlike some older androgen receptor inhibitors, darolutamide has a distinct molecular structure that prevents it from easily crossing the blood-brain barrier. This unique characteristic significantly reduces the incidence of central nervous system side effects, such as severe fatigue, cognitive impairment, and the risk of seizures.[4][5]

Throughout the 96-week treatment period, the rate of adverse events leading to treatment discontinuation was remarkably similar between the darolutamide group and the control group. Patients were largely able to maintain their daily routines and physical activities, which is essential for preserving cardiovascular health during prolonged hormone therapy.[2][6]

For clinical oncologists, the ability to halve the risk of metastatic spread without drastically compromising a patient's quality of life represents a major therapeutic victory. It translates clinical efficacy into a regimen that men can actually tolerate for the nearly two years required to complete the protocol.[1][3]

A shifting treatment landscape

Bayer’s Nubeqa is already a well-established tool in the urologic oncology arsenal, holding two existing regulatory approvals for non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. This new data broadens its potential application to an even earlier stage of the disease, where the primary goal is still a definitive cure.[3][5]

Following the ESMO 2026 presentation, Bayer is expected to submit the DASL-HiCaP trial data to the US Food and Drug Administration and the European Medicines Agency. Regulatory applications for this expanded indication will likely be filed in late 2026, setting the stage for potential formal approvals by mid-2027.[3][4]

If approved for this localized setting, the addition of darolutamide will require healthcare systems to adjust their reimbursement models. Adding a novel, patented oral therapy to a standard radiation protocol increases the upfront cost of care, though health economists argue it prevents the far greater expenses associated with treating advanced metastatic bone disease.[4][5]

The success of this trial also opens the door for further research into treatment de-escalation for patients who show exceptional responses. Future studies may explore whether men who achieve a rapid, deep response to the darolutamide combination might safely skip radiation therapy altogether, sparing them from localized pelvic toxicity.[1][5]

What patients should ask

For men recently diagnosed with localized prostate cancer, this development underscores the importance of accurate risk stratification before beginning any treatment. Not all localized cancers require this intensified approach; low-risk and intermediate-risk tumors are often managed effectively with active surveillance or single-modality therapy.[2][6]

Patients should ask their urologists and radiation oncologists to clearly define their risk category based on their Gleason score, PSA levels, and advanced imaging results. Those placed in the very high-risk category should explicitly discuss whether they are candidates for intensified systemic therapy alongside their localized treatments.[1][2]

Ultimately, the integration of darolutamide into the localized setting represents a proactive strike against a disease that has historically been allowed to dictate the timeline. By hitting the cancer harder and earlier, oncologists are maximizing the window for a permanent cure.[3][4]

The next verifiable milestone for this treatment protocol will be the FDA's acceptance of Bayer's supplemental new drug application, expected in early 2027. Until then, the ESMO data provides a clear, evidence-based roadmap for physicians managing the most aggressive forms of localized prostate cancer.[3][6]